A5009816072- Ovarian cancer diagnosis and treatment
- Virus-based gene therapy research
- Endometrial and Cervical Cancer Treatments
- Cancer Research and Treatments
- Cervical Cancer and HPV Research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- Intraperitoneal and Appendiceal Malignancies
- RNA Interference and Gene Delivery
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Viral gastroenteritis research and epidemiology
- Uterine Myomas and Treatments
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Nanoplatforms for cancer theranostics
- Advances in Oncology and Radiotherapy
- Endometriosis Research and Treatment
- PARP inhibition in cancer therapy
- Reproductive Biology and Fertility
- HER2/EGFR in Cancer Research
- Immune cells in cancer
Vanderbilt University Medical Center
1995-2024
Breast Cancer Research Foundation
2019-2024
Vanderbilt-Ingram Cancer Center
2017-2024
University of Alabama at Birmingham
2010-2023
Vanderbilt University
2017-2023
Virginia Commonwealth University
2016
Woman's Cancer Foundation
2011-2016
Cedars-Sinai Medical Center
2016
University of Alabama
1997-2015
Artifex University
2015
PURPOSE: To assess progression-free survival (PFS) and overall (OS) in patients with suboptimally debulked epithelial ovarian cancer receiving cisplatin (100 mg/m 2 ) or 24-hour infusion paclitaxel (200 the combination of (135 followed by (75 ). PATIENTS AND METHODS: After stratification for disease measurability, were randomized to receive six cycles one treatments every 3 weeks. If measurable, complete response (CR) partial (PR) was determined. RESULTS: Six hundred fourteen 648 who entered...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States and country’s fifth most common mortality women. A major challenge treating that patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating ovary, fallopian tube, or peritoneum, as these are all managed a similar manner. Most recommendations based on data with subtypes─high-grade serous grade 2/3 endometrioid. The also include specifically for less cancers,...
PURPOSE: Progestins have definite activity against advanced or recurrent endometrial carcinoma. Both parenteral and oral progestins yield similar serum levels response rates, which range from 18% to 34%. The one major study that used medroxyprogesterone acetate (MPA) noted a rate at the lower end of (18%) much poorer progression-free overall survival times (4 10.5 months, respectively) than previously reported. present sought confirm this earlier MPA, assess importance prognostic factors...
To determine whether continuing paclitaxel for an extended time period in women with advanced ovarian cancer who had achieved a clinically defined complete response to platinum/paclitaxel-based chemotherapy could prolong subsequent progression-free survival (PFS) and affect ultimate survival.Patients were randomly assigned either three or 12 cycles of single-agent administered every 28 days then followed up overall survival.As September 6, 2001, 277 patients (262 assessable) entered the...
Abstract Purpose: Within heterogeneous tumors, subpopulations often labeled cancer stem cells (CSC) have been identified that enhanced tumorigenicity and chemoresistance in ex vivo models. However, whether these populations are more capable of surviving chemotherapy de novo tumors is unknown. Experimental Design: We examined 45 matched primary/recurrent tumor pairs high-grade ovarian adenocarcinomas for expression CSC markers ALDH1A1, CD44, CD133 using immunohistochemistry. Tumors collected...
This selection from the NCCN Guidelines for Ovarian Cancer focuses on less common ovarian histopathologies (LCOHs), because new algorithms were added LCOHs and current revised 2016 update. The include clear cell carcinomas, mucinous grade 1 (low-grade) serous carcinomas/endometrioid epithelial carcinomas. also carcinosarcomas (malignant mixed Müllerian tumors of ovary), borderline (also known as low malignant potential tumors), sex cord-stromal tumors, germ tumors.
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years diagnosis. A major challenge treating that most have advanced disease at initial The best outcomes are observed whose primary treatment includes complete resection all visible plus combination platinum-based chemotherapy. Research efforts focused on neoadjuvant treatments may improve resectability, as well systemic therapies providing improved long-term...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations diagnosis, evaluation, treatment, and follow-up ovarian, fallopian tube, primary peritoneal cancers. These Insights summarize panel discussion behind recent important updates to guidelines, including revised guidance on alternative chemotherapy regimens advanced age and/or...
These NCCN Guidelines Insights focus on the major updates for 2012 Clinical Practice in Oncology (NCCN Guidelines) Ovarian Cancer by describing how and why new recommendations were made. The 6 update topics selected based recent important guidelines debate among panel members about clinical trials, include: 1) screening, 2) diagnostic tests assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) adjuvant bevacizumab combination with 5) therapy recurrent disease, 6)...
Adenovirus serotype 5 (Ad5) displays unparalleled gene transfer efficacy to cells with high coxsackie-adenovirus receptor (CAR) expression. Unfortunately, isolated from clinical human cancers, both ovarian and other types, express highly variable often low levels of CAR. Fortunately, native Ad5 tropism can be modified circumvent CAR deficiency enhance infectivity. Ad5/3luc1 incorporates the 3 fiber knob binds a distinct CAR, while Ad5lucRGD is an RGD-4C motif, allowing CAR-independent...
Because the combination of multiple modalities for cancer treatment is more likely to generate potent therapeutic effects control cancer, we have explored chemotherapy using cisplatin, which routinely used in advanced cervical with immunotherapy DNA vaccines encoding calreticulin (CRT) linked human papillomavirus type 16 E7 antigen (CRT/E7) a preclinical model.We characterized cisplatin CRT/E7 vaccine different regimen its potential ability E7-specific CD8+ T-cell immune responses as well...
Abstract It is increasingly recognized that microbes reside in and on human body sites play major roles modifying the pathogenesis of several diseases, including cancer. However, specific or microbial communities can be mechanistically linked to cervical carcinogenesis remain largely unexplored. The purpose study was examine association between microbiota high-grade intraepithelial neoplasia (CIN 2+) women infected with high-risk (HR) papillomaviruses (HPV) assess whether are associated...
Abstract Purpose: Jagged1, a Notch ligand, is expressed on both tumor epithelial and endothelial cells therefore may be amenable to dual targeting of the stroma malignant cell compartments microenvironment. Experimental Design: We describe in vitro effects Jagged1 ovarian cancer vivo independent stromal using species-specific human or murine siRNA constructs incorporated into chitosan nanoparticles delivered intravenously an orthotopic mouse model. Results: expression was prominent SKOV3ip1...
Purpose: Study distribution, pharmacokinetics, and safety of intraperitoneal (IP) 212Pb-TCMC-trastuzumab in patients with HER-2-expressing malignancy. Experimental Design: IP was delivered, after 4 mg/kg intravenous (IV) trastuzumab, to 3 cancer who had failed standard therapies. Patients were monitored for toxicity pharmacokinetics/dosimetry parameters. Results: Imaging studies 0.2 mCi/m2 (7.4 MBq/m2) show little redistribution out the peritoneal cavity no significant uptake major organs....
// Zachary C. Dobbin 1,2 , Ashwini A. Katre 1 Adam D. Steg Britt K. Erickson Monjri M. Shah Ronald Alvarez Michael G. Conner 3 David Schneider 4 Dongquan Chen 5 and Charles N. Landen 6 Division of Gynecologic Oncology, Department Obstetrics Gynecology, University Alabama at Birmingham 2 NIH Medical Scientist Training Program, Pathology, Biochemistry Molecular Genetics, Preventative Medicine, The Virginia, Charlottesville, VA Correspondence: Jr, email: Keywords : Ovarian Cancer,...
Patients presenting with microhematuria represent a heterogeneous population broad spectrum of risk for genitourinary malignancy. Recognizing that patient-specific characteristics modify the underlying malignant etiologies, this guideline sought to provide personalized diagnostic testing strategy.The systematic review incorporated evidence published from January 2010 through February 2019, an updated literature search include studies up December 2019. Evidence-based statements were developed...